Details
Stereochemistry | ACHIRAL |
Molecular Formula | Na.2H2O.H2O4P |
Molecular Weight | 156.0076 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].OP(O)([O-])=O
InChI
InChIKey=VBJGJHBYWREJQD-UHFFFAOYSA-M
InChI=1S/Na.H3O4P.2H2O/c;1-5(2,3)4;;/h;(H3,1,2,3,4);2*1H2/q+1;;;/p-1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H3O4P |
Molecular Weight | 97.9952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PROCALAMINE Approved UseProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. Launch Date1982 |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Primary | SODIUM PHOSPHATES INJECTION Approved UseSodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions. |
Sample Use Guides
lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26018307
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:54 GMT 2025
by
admin
on
Mon Mar 31 18:02:54 GMT 2025
|
Record UNII |
5QWK665956
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29730
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5QWK665956
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
314837
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
ALTERNATIVE | |||
|
23673460
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
C66551
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
13472-35-0
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
SUB12287MIG
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
SUB53031
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
100000092043
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
1311311
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
ALTERNATIVE | RxNorm | ||
|
DBSALT001970
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
DTXSID90158903
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
1311286
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY | |||
|
5QWK665956
Created by
admin on Mon Mar 31 18:02:54 GMT 2025 , Edited by admin on Mon Mar 31 18:02:54 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|